JP2015512951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512951A5 JP2015512951A5 JP2015505972A JP2015505972A JP2015512951A5 JP 2015512951 A5 JP2015512951 A5 JP 2015512951A5 JP 2015505972 A JP2015505972 A JP 2015505972A JP 2015505972 A JP2015505972 A JP 2015505972A JP 2015512951 A5 JP2015512951 A5 JP 2015512951A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disorder
- dementia
- pharmaceutical composition
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical group 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 201000002055 autistic disease Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 201000011240 frontotemporal dementia Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 210000004227 Basal Ganglia Anatomy 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 201000010374 Down syndrome Diseases 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- 206010019233 Headache Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010022568 Intermittent explosive disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000011585 Pick's disease Diseases 0.000 claims 1
- 208000003055 Prion Disease Diseases 0.000 claims 1
- 206010061920 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000008779 central nervous system disease Diseases 0.000 claims 1
- 230000001054 cortical Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 201000002146 gastrointestinal system disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 201000008839 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 1
- 230000000697 serotonin reuptake Effects 0.000 claims 1
- 201000007196 sexual disease Diseases 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 201000004810 vascular dementia Diseases 0.000 claims 1
Claims (20)
- R2がOR3である、請求項1記載の化合物。
- R1がC1−6アルキルである、請求項1または2記載の化合物。
- R1がメチルである、請求項1記載の化合物。
- R2がOR3であり、R3がC1−6アルキルである、請求項1ないし4のいずれか一項記載の化合物。
- R2がOR3であり、R3がメチルである、請求項5記載の化合物。
- XがN(C1−4アルキル)である、請求項1ないし6のいずれか一項記載の化合物。
- XがOである、請求項1ないし6のいずれか一項記載の化合物。
- XがN(H)である、請求項1ないし6のいずれか一項記載の化合物。
- XがN(CH3)である、請求項7記載の化合物。
- 該化合物が塩形態である、請求項1ないし12のいずれか一項記載の化合物。
- 該塩が、トルエンスルホン酸、フマル酸およびリン酸付加塩からなる群から選択される、請求項13記載の化合物。
- 請求項1ないし14のいずれか一項記載の化合物を、薬学的に許容される希釈剤または担体と組み合わせて、または混合して含む、医薬組成物。
- 中枢神経系障害の処置または予防のための、請求項15記載の医薬組成物。
- 該障害が、肥満、不安、鬱病、精神病、統合失調症、睡眠障害、性的障害、偏頭痛、頭部痛と関係する病状、社交不安障害、動揺、認知症における動揺、自閉症における動揺および関連する自閉性障害、胃腸管の運動機能障害のような消化器系障害、外傷後ストレス障害、衝動調節障害、間欠性爆発性障害からなる群から選択される、請求項16記載の医薬組成物。
- 該障害が認知症と関連する1種以上の障害である、請求項16記載の医薬組成物。
- 障害が軽度認知障害および老人性認知症、アルツハイマー病、ピック病、前頭側頭型認知症、進行性核上性麻痺(parasupranuclear palsy)、レビー小体型認知症、血管性認知症、ハンチントン病、パーキンソン病、多発性硬化症、筋萎縮性側索硬化症、ダウン症候群、老人性鬱病、ウェルニッケ・コルサコフ症候群、大脳皮質基底核変性症およびプリオン病を含む認知症疾患と関連する障害である、請求項18に記載の医薬組成物。
- 該障害がセロトニン5−HT2A、ドーパミンD2および/またはセロトニン再取り込みトランスポーター(SERT)経路が関係する障害である、請求項16または17記載の医薬組成物。
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261624292P | 2012-04-14 | 2012-04-14 | |
US201261624291P | 2012-04-14 | 2012-04-14 | |
US201261624293P | 2012-04-14 | 2012-04-14 | |
US61/624,292 | 2012-04-14 | ||
US61/624,293 | 2012-04-14 | ||
US61/624,291 | 2012-04-14 | ||
US201261671723P | 2012-07-14 | 2012-07-14 | |
US201261671713P | 2012-07-14 | 2012-07-14 | |
US61/671,723 | 2012-07-14 | ||
US61/671,713 | 2012-07-14 | ||
PCT/US2013/036514 WO2013155505A1 (en) | 2012-04-14 | 2013-04-14 | Organic compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015512951A JP2015512951A (ja) | 2015-04-30 |
JP2015512951A5 true JP2015512951A5 (ja) | 2016-06-09 |
JP6242855B2 JP6242855B2 (ja) | 2017-12-06 |
Family
ID=49328233
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015505972A Active JP6242855B2 (ja) | 2012-04-14 | 2013-04-14 | 有機化合物 |
JP2015505973A Withdrawn JP2015514135A (ja) | 2012-04-14 | 2013-04-14 | 新規組成物および方法 |
JP2015505971A Active JP6334511B2 (ja) | 2012-04-14 | 2013-04-14 | 新規方法 |
JP2018107717A Withdrawn JP2018168161A (ja) | 2012-04-14 | 2018-06-05 | 新規組成物および方法 |
JP2021035948A Pending JP2021098724A (ja) | 2012-04-14 | 2021-03-08 | 新規組成物および方法 |
JP2023136052A Pending JP2023159345A (ja) | 2012-04-14 | 2023-08-24 | 新規組成物および方法 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015505973A Withdrawn JP2015514135A (ja) | 2012-04-14 | 2013-04-14 | 新規組成物および方法 |
JP2015505971A Active JP6334511B2 (ja) | 2012-04-14 | 2013-04-14 | 新規方法 |
JP2018107717A Withdrawn JP2018168161A (ja) | 2012-04-14 | 2018-06-05 | 新規組成物および方法 |
JP2021035948A Pending JP2021098724A (ja) | 2012-04-14 | 2021-03-08 | 新規組成物および方法 |
JP2023136052A Pending JP2023159345A (ja) | 2012-04-14 | 2023-08-24 | 新規組成物および方法 |
Country Status (13)
Country | Link |
---|---|
US (8) | US20150080404A1 (ja) |
EP (4) | EP2836212A4 (ja) |
JP (6) | JP6242855B2 (ja) |
KR (1) | KR20140146192A (ja) |
CN (1) | CN104519886B (ja) |
AU (1) | AU2013245702A1 (ja) |
CA (1) | CA2870303A1 (ja) |
ES (1) | ES2727815T3 (ja) |
HK (1) | HK1206630A1 (ja) |
IN (1) | IN2014DN08562A (ja) |
MX (1) | MX2014012374A (ja) |
RU (1) | RU2014145682A (ja) |
WO (3) | WO2013155505A1 (ja) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5567349B2 (ja) | 2007-03-12 | 2014-08-06 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ−カルボリンの合成 |
CN102046175B (zh) | 2008-03-12 | 2015-08-12 | 细胞内治疗公司 | 取代的杂环稠合的γ-咔啉固体 |
US8598119B2 (en) * | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
JP5894574B2 (ja) | 2010-04-22 | 2016-03-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
ES2727815T3 (es) | 2012-04-14 | 2019-10-18 | Intra Cellular Therapies Inc | Tratamiento del TEPT y de trastornos del control de impulsos |
US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
EP2968320B1 (en) | 2013-03-15 | 2020-11-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR102495941B1 (ko) | 2013-12-03 | 2023-02-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
BR112016023162B1 (pt) * | 2014-04-04 | 2022-11-29 | Intra-Cellular Therapies, Inc | Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central |
MX2016013046A (es) * | 2014-04-04 | 2017-02-15 | Intra-Cellular Therapies Inc | Compuestos organicos. |
CN104003987B (zh) * | 2014-06-03 | 2016-03-23 | 中国药科大学 | 他克林-β-咔啉异二连体类多功能胆碱酯酶抑制剂 |
US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
WO2016205631A1 (en) * | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders |
BR112018015283B1 (pt) * | 2016-01-26 | 2023-09-26 | Intra-Cellular Therapies, Inc | Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central |
EP3888656A1 (en) * | 2016-03-25 | 2021-10-06 | Intra-Cellular Therapies, Inc. | Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder |
EP3436016B1 (en) | 2016-03-28 | 2022-04-27 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
WO2017172795A1 (en) * | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
EP3436455A4 (en) | 2016-03-28 | 2019-09-04 | Intra-Cellular Therapies, Inc. | NOVEL SALTS AND CRYSTALS |
US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
US11433253B2 (en) | 2017-02-15 | 2022-09-06 | The Regents Of The University Of California | Light therapy system and methods of use |
EP3582852A4 (en) | 2017-02-15 | 2020-11-25 | The Regents of the University of California | IMPROVED LIGHT THERAPY SYSTEM AND METHOD OF USE |
CA3054841A1 (en) * | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
WO2018189646A1 (en) | 2017-04-10 | 2018-10-18 | Dr. Reddy's Laboratories Limited | AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE |
WO2019023063A1 (en) * | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
MX2020000968A (es) * | 2017-07-26 | 2020-09-28 | Intra Cellular Therapies Inc | Compuestos organicos. |
CN111107847A (zh) * | 2017-09-26 | 2020-05-05 | 细胞内治疗公司 | 新的盐和晶体 |
MX2020009668A (es) | 2018-03-16 | 2021-01-08 | Intra Cellular Therapies Inc | Métodos novedosos. |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
EP3801527A4 (en) * | 2018-06-08 | 2022-03-30 | Intra-Cellular Therapies, Inc. | NEW METHODS |
JP7483671B2 (ja) * | 2018-06-11 | 2024-05-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ-カルボリン類合成 |
CA3108304A1 (en) | 2018-06-21 | 2019-12-26 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
EP3843738A4 (en) * | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
EP3846778A1 (en) | 2018-09-07 | 2021-07-14 | Aquestive Therapeutics, Inc. | Oral film compositions and dosage forms having precise active dissolution profiles |
EP4134101A1 (en) | 2019-07-07 | 2023-02-15 | Intra-Cellular Therapies, Inc. | Deuterated lumateperone for the treatment of the bipolar ii disorder |
CN115003279A (zh) | 2019-11-01 | 2022-09-02 | 阿奎斯蒂弗医疗股份有限公司 | 前药组合物和治疗方法 |
KR20220126287A (ko) | 2019-11-14 | 2022-09-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 멀티모달 조성물 및 치료 방법 |
EP4072554A4 (en) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUND |
JP2024505429A (ja) | 2021-01-15 | 2024-02-06 | アクエスティブ セラピューティクス インコーポレイテッド | プロドラッグ組成物及び治療の方法 |
WO2022192476A1 (en) | 2021-03-09 | 2022-09-15 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
WO2023225620A1 (en) | 2022-05-18 | 2023-11-23 | Intra-Cellular Therapies, Inc. | Novel methods |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
US3606908A (en) | 1969-11-26 | 1971-09-21 | Trico Products Corp | Ventilation system for volatile fluid |
US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
JPS5014494A (ja) * | 1973-06-11 | 1975-02-15 | ||
US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
SE8304361D0 (sv) * | 1983-08-10 | 1983-08-10 | Ferrosan Ab | Novel 1-acylpiperazine derivatives novel 1-acylpiperazine derivatives |
CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
JPS6175A (ja) * | 1984-03-06 | 1986-01-06 | ブリストル−マイア−ズ コムパニ− | 神経弛緩剤、1‐フルオロフェニルブチル‐4‐(5‐ハロ‐2‐ピリミジニル)ピペラジン誘導体 |
IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
ATE90683T1 (de) | 1986-03-19 | 1993-07-15 | Kumiai Chemical Industry Co | 5h-1,3,4-thiazol(3,2-a>pyrimidin-5-on-derivate und diese enthaltende fungizide zubereitungen. |
JP2641443B2 (ja) | 1986-04-07 | 1997-08-13 | クミアイ化学工業株式会社 | 5H−1,3,4−チアジアゾロ〔3,2−a〕ピリミジン−5−オン誘導体及びこれを有効成分とする農園芸用殺菌剤 |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
WO1999018057A1 (en) | 1997-10-06 | 1999-04-15 | Massachusetts Institute Of Technology | Preparation of diaryl ether by condensation reactions |
US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
ATE229499T1 (de) | 1998-02-26 | 2002-12-15 | Massachusetts Inst Technology | Metallkatalysierte arylierungen und vinylierungen von hydrazinen, hydrazonen, hydroxylaminen und oximen |
US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
ATE360634T1 (de) | 1998-07-10 | 2007-05-15 | Massachusetts Inst Technology | Ligande für metalle und verbesserte metall- katalysierte verfahren, die darauf basieren |
US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
CN1161101C (zh) | 1998-12-17 | 2004-08-11 | 阿尔扎有限公司 | 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统 |
US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
AR023574A1 (es) | 1999-04-23 | 2002-09-04 | Pharmacia & Upjohn Co Llc | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios |
US6552017B1 (en) * | 1999-06-15 | 2003-04-22 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
MXPA03005438A (es) | 2000-12-20 | 2004-05-05 | Bristol Myers Squibb Co | Pirioindoles substituidos como agonistas y antagonistas de serotonina. |
US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
CN1266112C (zh) | 2001-04-24 | 2006-07-26 | 麻省理工学院 | 铜-催化的碳-杂原子键和碳-碳键的形成 |
MXPA04001203A (es) | 2001-08-08 | 2004-05-20 | Pharmacia & Upjhon Company | 1-h-pirido[4,3-b] indoles terapeuticos. |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
PT1539115E (pt) | 2002-07-29 | 2008-01-14 | Alza Corp | Métodos e formas de dosagem para libertação controlada de paliperidona |
AU2003257062A1 (en) | 2002-08-02 | 2004-02-23 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
AU2003287433A1 (en) | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
AU2003303210A1 (en) | 2002-12-19 | 2004-07-14 | Bristol-Myers Squibb Company | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
KR101095939B1 (ko) | 2003-01-16 | 2011-12-19 | 아카디아 파마슈티칼스 인코포레이티드 | 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2a/2c 리셉터 역작용제 |
US7462641B2 (en) | 2003-07-21 | 2008-12-09 | Smithkline Beecham Corporation | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
EP1756102A1 (en) | 2004-03-05 | 2007-02-28 | Pharma C S.A. | 8-PHENOXY-GammaCARBOLINE DERIVATIVES |
US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
US8461148B2 (en) | 2004-09-20 | 2013-06-11 | Icahn School Of Medicine At Mount Sinai | Use of memantine (namenda) to treat autism, compulsivity and impulsivity |
WO2006032999A1 (en) | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-methyl hydroxyethylamine useful in treating cns conditions |
ES2338139T3 (es) | 2004-12-15 | 2010-05-04 | F. Hoffmann-La Roche Ag | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador de la glicina i (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
CN103467471A (zh) * | 2005-06-06 | 2013-12-25 | 武田药品工业株式会社 | 有机化合物 |
JP5567349B2 (ja) * | 2007-03-12 | 2014-08-06 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ−カルボリンの合成 |
CA2719824A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
NZ586963A (en) | 2008-02-05 | 2012-11-30 | Clera Inc | Use of dopamine d2 receptor inhibitors for alleviating depression or improving cognition |
CN102046175B (zh) | 2008-03-12 | 2015-08-12 | 细胞内治疗公司 | 取代的杂环稠合的γ-咔啉固体 |
US8598119B2 (en) | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
JP5894574B2 (ja) | 2010-04-22 | 2016-03-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
ES2727815T3 (es) * | 2012-04-14 | 2019-10-18 | Intra Cellular Therapies Inc | Tratamiento del TEPT y de trastornos del control de impulsos |
US10011602B2 (en) | 2012-07-06 | 2018-07-03 | The University Of Melbourne | Immunological reagents and uses therefor |
EP2968320B1 (en) | 2013-03-15 | 2020-11-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9161061B2 (en) | 2013-03-15 | 2015-10-13 | Pictech Management Limited | Data storage and exchange device for color space encoded images |
KR102495941B1 (ko) | 2013-12-03 | 2023-02-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
MX2016013046A (es) | 2014-04-04 | 2017-02-15 | Intra-Cellular Therapies Inc | Compuestos organicos. |
BR112016023162B1 (pt) | 2014-04-04 | 2022-11-29 | Intra-Cellular Therapies, Inc | Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central |
US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
BR112018015283B1 (pt) | 2016-01-26 | 2023-09-26 | Intra-Cellular Therapies, Inc | Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central |
EP3888656A1 (en) | 2016-03-25 | 2021-10-06 | Intra-Cellular Therapies, Inc. | Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder |
EP3436455A4 (en) | 2016-03-28 | 2019-09-04 | Intra-Cellular Therapies, Inc. | NOVEL SALTS AND CRYSTALS |
US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
CA3054841A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
WO2019023063A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
MX2020000968A (es) | 2017-07-26 | 2020-09-28 | Intra Cellular Therapies Inc | Compuestos organicos. |
-
2013
- 2013-04-14 ES ES13776189T patent/ES2727815T3/es active Active
- 2013-04-14 CN CN201380030774.2A patent/CN104519886B/zh not_active Expired - Fee Related
- 2013-04-14 WO PCT/US2013/036514 patent/WO2013155505A1/en active Application Filing
- 2013-04-14 EP EP13776208.4A patent/EP2836212A4/en not_active Ceased
- 2013-04-14 JP JP2015505972A patent/JP6242855B2/ja active Active
- 2013-04-14 CA CA2870303A patent/CA2870303A1/en not_active Abandoned
- 2013-04-14 AU AU2013245702A patent/AU2013245702A1/en not_active Abandoned
- 2013-04-14 RU RU2014145682A patent/RU2014145682A/ru not_active Application Discontinuation
- 2013-04-14 EP EP20190036.2A patent/EP3791879A1/en active Pending
- 2013-04-14 IN IN8562DEN2014 patent/IN2014DN08562A/en unknown
- 2013-04-14 WO PCT/US2013/036512 patent/WO2013155504A1/en active Application Filing
- 2013-04-14 EP EP13776297.7A patent/EP2836213B1/en active Active
- 2013-04-14 EP EP13776189.6A patent/EP2836211B1/en active Active
- 2013-04-14 KR KR1020147031752A patent/KR20140146192A/ko not_active Application Discontinuation
- 2013-04-14 US US14/394,470 patent/US20150080404A1/en not_active Abandoned
- 2013-04-14 JP JP2015505973A patent/JP2015514135A/ja not_active Withdrawn
- 2013-04-14 US US14/394,469 patent/US11053245B2/en active Active
- 2013-04-14 WO PCT/US2013/036515 patent/WO2013155506A1/en active Application Filing
- 2013-04-14 JP JP2015505971A patent/JP6334511B2/ja active Active
- 2013-04-14 US US14/394,467 patent/US9428506B2/en active Active
- 2013-04-14 MX MX2014012374A patent/MX2014012374A/es unknown
-
2015
- 2015-07-31 HK HK15107356.6A patent/HK1206630A1/xx not_active IP Right Cessation
-
2018
- 2018-06-05 JP JP2018107717A patent/JP2018168161A/ja not_active Withdrawn
-
2019
- 2019-09-27 US US16/585,251 patent/US11124514B2/en active Active
-
2020
- 2020-07-10 US US16/926,552 patent/US20210002280A1/en active Pending
- 2020-07-10 US US16/926,551 patent/US20200407362A1/en active Pending
-
2021
- 2021-03-08 JP JP2021035948A patent/JP2021098724A/ja active Pending
- 2021-08-18 US US17/405,736 patent/US11958852B2/en active Active
-
2023
- 2023-08-24 JP JP2023136052A patent/JP2023159345A/ja active Pending
-
2024
- 2024-03-11 US US18/601,923 patent/US20240208974A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015512951A5 (ja) | ||
RU2014145682A (ru) | Органические соединения | |
RU2018130727A (ru) | Органические соединения | |
HRP20210526T1 (hr) | Oksisteroli i postupci za njihovu uporabu | |
JP2015511958A5 (ja) | ||
JP2018519329A5 (ja) | ||
HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
JP2018519351A5 (ja) | ||
JP2018519328A5 (ja) | ||
JP2017531020A5 (ja) | ||
RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
JP2014526469A5 (ja) | ||
JP2020502092A5 (ja) | ||
JP2017533968A5 (ja) | ||
JP2015537020A5 (ja) | ||
JP2013032389A5 (ja) | ||
JP2017514910A5 (ja) | ||
MY167396A (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
JP2015508092A5 (ja) | ||
JP2015523406A5 (ja) | ||
JP2016537338A5 (ja) | ||
JP2012515150A5 (ja) | ||
MY169069A (en) | Prodrug of fluorine-containing amino acid | |
JP2012532858A5 (ja) | ||
JP2016537432A5 (ja) |